Highlights LumiraDx Limited

Equities

LMDXF

KYG5709L1095

Delayed OTC Markets Other stock markets 17:34:34 16/05/2024 BST			5-day change	1st Jan Change
0.019 ^USD	-11.63%		-18.45%	-69.79%

01-08	Top Midday Decliners	MT
01-08	LumiraDx Limited(OTCPK:LMDX.F) dropped from NASDAQ Composite Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roche to buy part of LumiraDx diagnostics platform for $295 million	12-29	RE
LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche	12-29	DJ
Earnings Flash (LMDX) LUMIRADX Reports Q2 Revenue $21M, vs. Street Est of $21.5M	24/08/23	MT
LumiraDx Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
LumiraDx Limited Signs Commercial Distribution Agreement with Axon Lab AG for the Commercialization of its LumiraDx Platform and Tests	31/07/23	CI
LumiraDx Files 510(k) Application With US FDA for COVID-19 Test	30/06/23	MT
Powell Testimony Eyed Amid Lower Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	21/06/23	MT
LumiraDx Says it Obtained UK Regulatory 'Validation' for Use of Coronavirus Tests	21/06/23	MT
LumiraDx Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23	CI
Earnings Flash (LMDX) LUMIRADX Reports Q1 Revenue $22.2M, vs. Street Est of $19.4M	16/05/23	MT
LumiraDx Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	21/03/23	CI
LumiraDx Limited Reports Earnings Results for the Full Year Ended December 31, 2022	21/03/23	CI
Earnings Flash (LMDX) LUMIRADX Reports Q4 Revenue $41.1M, vs. Street Est of $43.5M	21/03/23	MT
Lumiradx Receives FDA Emergency Use Authorization and UK CTDA Approval for Its Fast Lab Solutions Multiplex Covid and Influenza Molecular Assay	06/02/23	CI
LumiraDx Gets Noncompliance Notice From Nasdaq	01/02/23	MT
LumiraDx Limited Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK	31/01/23	CI
LumiraDx Limited Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test	14/12/22	CI
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test	14/11/22	CI
Earnings Flash (LMDX) LUMIRADX Posts Q3 Revenue $42.2M, vs. Street Est of $34.8M	09/11/22	MT
Earnings Flash (LMDX) LUMIRADX Reports Q3 Loss $-0.21, vs. Street Est of $-0.27	09/11/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LumiraDx Limited

Equities

LMDXF

KYG5709L1095

Highlights

Filters